- Home
- WATT vs AYTU Comparison
WATT vs AYTU Comparison
Compare WATT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- AYTU
- Stock Information
- Founded
- WATT 2012
- AYTU N/A
- Country
- WATT United States
- AYTU United States
- Employees
- WATT N/A
- AYTU N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- AYTU Health Care
- Exchange
- WATT Nasdaq
- AYTU Nasdaq
- Market Cap
- WATT 9.1M
- AYTU 8.3M
- IPO Year
- WATT 2014
- AYTU N/A
- Fundamental
- Price
- WATT $0.28
- AYTU $1.78
- Analyst Decision
- WATT
- AYTU
- Analyst Count
- WATT 0
- AYTU 0
- Target Price
- WATT N/A
- AYTU N/A
- AVG Volume (30 Days)
- WATT 2.0M
- AYTU 3.7M
- Earning Date
- WATT 05-13-2025
- AYTU 05-14-2025
- Dividend Yield
- WATT N/A
- AYTU N/A
- EPS Growth
- WATT N/A
- AYTU N/A
- EPS
- WATT N/A
- AYTU N/A
- Revenue
- WATT $1,047,000.00
- AYTU $77,691,000.00
- Revenue This Year
- WATT $1,028.91
- AYTU N/A
- Revenue Next Year
- WATT N/A
- AYTU $8.14
- P/E Ratio
- WATT N/A
- AYTU $6.70
- Revenue Growth
- WATT 137.41
- AYTU N/A
- 52 Week Low
- WATT $0.12
- AYTU $0.95
- 52 Week High
- WATT $2.70
- AYTU $3.23
- Technical
- Relative Strength Index (RSI)
- WATT 50.45
- AYTU 55.38
- Support Level
- WATT $0.27
- AYTU $1.90
- Resistance Level
- WATT $0.29
- AYTU $2.70
- Average True Range (ATR)
- WATT 0.02
- AYTU 0.20
- MACD
- WATT 0.00
- AYTU -0.01
- Stochastic Oscillator
- WATT 40.25
- AYTU 37.84
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.